# LAI Intelligence Weekly – December 8, 2025

This week's intelligence highlights competitive positioning in hemophilia, regulatory developments across key markets, and strategic marketing investments in immunology. Notable activity includes safety probes, first-in-class approvals, and industry efforts to address antimicrobial resistance.

## TL;DR

- Pfizer advances Hympavzi with new Phase 3 data to compete in the hemophilia market
- FDA investigates Takeda safety signal while Otsuka secures first-in-class IgA nephropathy approval
- AbbVie leads November pharma TV advertising with Skyrizi, outpacing J&J's Tremfya

---

## Top Signals – LAI Ecosystem

Key developments shaping the competitive landscape across hemophilia, regulatory milestones, and commercial strategies.

**ASH: Pfizer, aiming to level the hemophilia playing field, trots out new Hympavzi data**  
Pfizer presented new Phase 3 data for Hympavzi at ASH, positioning the hemophilia drug to compete more effectively against rival treatments. The data release represents a strategic move to strengthen Hympavzi's competitive standing in the hemophilia market.  
[Read more](https://www.fiercepharma.com/pharma/ash-pfizer-aiming-level-hemophilia-playing-field-trots-out-hympavzi-inhibitors-data)

**Regulatory tracker: Agios awaits FDA decision as target date passes**  
Agios continues awaiting an FDA decision that has exceeded its target date, as Fierce Pharma tracks regulatory progress for in-market products. The tracker monitors geographic expansions and new indication approvals across the industry.  
[Read more](https://www.fiercepharma.com/pharma/fierce-pharma-regulatory-tracker-second-half-2025)

**AbbVie revs up Skyrizi spending to top TV ad totals in November, edging out J&J's Tremfya**  
AbbVie led pharmaceutical TV advertising in November with Skyrizi, narrowly surpassing J&J's Tremfya in spending. The investment follows a record-setting October for pharma advertising activity.  
[Read more](https://www.fiercepharma.com/marketing/abbvie-revs-skyrizi-spending-top-tv-ad-totals-november-edging-out-jjs-tremfya)

**Fierce Pharma Asia—FDA safety probe of Takeda drug; Otsuka kidney disease nod; ADC patent fight**  
The FDA is investigating a safety signal related to Takeda's rare disease medication Adzynma. Separately, Otsuka received first-in-class FDA approval for an IgA nephropathy treatment, while ADC patent litigation continues in the region.  
[Read more](https://www.fiercepharma.com/pharma/fda-safety-probe-takeda-drug-otsuka-kidney-disease-nod-adc-patent-fight)

**Pfizer, GSK, Shionogi sponsor London run of musical about antimicrobial resistance**  
Pfizer, GSK, and Shionogi are jointly sponsoring a London musical production focused on antimicrobial resistance awareness. The collaboration represents a public engagement effort by three major pharmaceutical companies on a critical health threat.  
[Read more](https://www.fiercepharma.com/marketing/pfizer-gsk-shionogi-sponsor-london-run-musical-about-antimicrobial-resistance)

---

*Newsletter générée par Vectora Inbox – Powered by Amazon Bedrock*
